These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16423907)

  • 1. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor.
    Ivandic BT; Schlick P; Staritz P; Kurz K; Katus HA; Giannitsis E
    Clin Chem; 2006 Mar; 52(3):383-8. PubMed ID: 16423907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of aspirin responsiveness by use of whole blood platelet aggregometry.
    Ivandic BT; Giannitsis E; Schlick P; Staritz P; Katus HA; Hohlfeld T
    Clin Chem; 2007 Apr; 53(4):614-9. PubMed ID: 17332149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention.
    Ivandic BT; Sausemuth M; Ibrahim H; Giannitsis E; Gawaz M; Katus HA
    Clin Chem; 2009 Jun; 55(6):1171-6. PubMed ID: 19359538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
    Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
    Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
    von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):199-204. PubMed ID: 15795539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer--comparison with two flow cytometric methods.
    Mueller T; Dieplinger B; Poelz W; Calatzis A; Haltmayer M
    Thromb Res; 2007; 121(2):249-58. PubMed ID: 17482663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable extent of clopidogrel responsiveness in patients after coronary stenting.
    Grossmann R; Sokolova O; Schnurr A; Bonz A; Porsche C; Obergfell A; Lengenfelder B; Walter U; Eigenthaler M
    Thromb Haemost; 2004 Dec; 92(6):1201-6. PubMed ID: 15583724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease.
    Matsagas M; Jagroop IA; Geroulakos G; Mikhailidis DP
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):115-20. PubMed ID: 12812379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
    Siller-Matula J; Schrör K; Wojta J; Huber K
    Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.